Clover Health (CLOV) CEO’s 313,476-share sale tied to RSU tax withholding
Clover Health Investments, Corp. (CLOV) CEO Andrew Toy sold 313,476 shares of Class A common stock at $5.32 per share. This sale was explicitly to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) and was a non-discretionary "sell to cover" transaction, as mandated by the company's equity incentive plans. Following the sale, Toy directly holds 9,609,825 shares, and the remaining RSUs will continue to vest quarterly through January 1, 2027.
Clover Health CEO Andrew Toy sells $1.67 million in stock By Investing.com
Clover Health CEO Andrew Toy sold 313,476 shares of Class A Common Stock for $1.67 million to cover tax withholding obligations related to vested restricted stock units. This sale was a "sell to cover" transaction and not a discretionary trade. The stock, trading near its 52-week high, appears overvalued according to InvestingPro analysis, despite a recent Medicare star rating upgrade and exceeding revenue expectations in Q1 2026.
Clover Health CEO Andrew Toy sells $1.67 million in stock
Clover Health CEO Andrew Toy sold 313,476 shares of Class A Common Stock for $1.67 million to cover tax obligations related to restricted stock units. This sale was a mandatory "sell to cover" transaction and not discretionary. The company recently reported Q1 2026 revenue of $749.2 million, exceeding analyst expectations, and received an upgrade to a 4.5-star Medicare rating after a favorable court decision.
[144] CLOVER HEALTH INVESTMENTS, CORP. /DE SEC Filing
This SEC filing details a Form 144 notice of proposed sale of securities for Clover Health Investments, Corp. (CLOV). The filing indicates an individual plans to sell 309,558 shares of Class A Common Stock, acquired through Restricted Stock Units as compensation, with an aggregate market value of $1,668,517.62 on July 1, 2026. The sale will be executed through Morgan Stanley Smith Barney LLC on the Nasdaq exchange.
ETFs Investing in Clover Health Investments Corp. Class A Stocks
This article provides a list of exchange-traded funds (ETFs) that hold Clover Health Investments Corp. Class A stocks. The funds are sorted by market value and include details such as issuer, management style, focus, expense ratio, assets under management (AUM), and price performance. The information is presented to help investors find accessible opportunities with lower risk.
CLOV SEC Filings - Clover Health Investments Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Clover Health Investments (CLOV) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event reports (8-K). It details recent insider transaction activity, such as share withholdings for tax purposes and stock sales by executives. The platform also offers AI-powered summaries of these documents and tracks key company announcements, like the 2026 outlook presentation.
7QD Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Clover Health Investments Corp. Class A (7QD) stock based on analyst opinions. It details maximum and minimum price estimates, historical price data, earnings information, and financial performance for the company, including revenue and net income. Additionally, it confirms that 7QD does not pay dividends and offers general information about the company's stock on TradingView.
Clover Health Investments Corp. Class A Actuals & Estimates (NASDAQ:CLOV)
This article provides an overview of Clover Health Investments Corp. (NASDAQ: CLOV), detailing its financial actuals and estimates. It covers the company's current stock price, historical highs and lows, market capitalization, and volatility. Additionally, it includes analysts' forecasts, recent earnings, revenue figures, and upcoming earnings report dates.
Clover Health Investments Corp. Class A Actuals & Estimates (BX:CLOV)
This article provides financial actuals and estimates for Clover Health Investments Corp. Class A (CLOV) traded on the BX Swiss exchange. It details analyst price targets, upcoming earnings dates, past earnings and revenue figures, and confirms that CLOV does not pay dividends. The company has 724 employees as of June 26, 2026, and offers guidance on how to buy its stocks.
Clover Health CEO Jamie Reynoso sells $11,280 in class A stock By Investing.com
Jamie Reynoso, CEO of Medicare Advantage at Clover Health Investments, sold 2,360 shares of Class A Common Stock worth $11,280 on June 17, 2026, as part of a Rule 10b5-1 trading plan. This sale occurred while Clover Health shares have risen 104% year-to-date and are trading near their 52-week high. The company recently reported mixed Q1 2026 earnings, exceeding revenue expectations but missing on EPS, and received an upgraded Medicare star rating to 4.5 following a favorable court ruling.
Clover Health CEO Jamie Reynoso sells $11,280 in class A stock By Investing.com
Clover Health CEO Jamie Reynoso sold 2,360 shares of Class A Common Stock worth $11,280 on June 17, 2026, through a pre-arranged trading plan. This sale occurred after the company's shares surged 104% year-to-date and were near their 52-week high, with InvestingPro analysis indicating the stock is overvalued. Despite this, Clover Health recently reported Q1 2026 revenue exceeding expectations and received an upgraded Medicare star rating to 4.5 following a favorable court ruling.
Clover Health CEO Jamie Reynoso sells $11,280 in class A stock
Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 2,360 shares of Class A Common Stock for a total of $11,280 on June 17, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred amidst a 104% year-to-date surge in Clover Health shares, leading to an InvestingPro analysis indicating the stock might be overvalued. The sale follows mixed Q1 2026 earnings for Clover Health and an upgraded Medicare star rating to 4.5 after a favorable court ruling.
Clover Health (CLOV) executive sells 2,360 shares in 10b5-1 plan
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, sold 2,360 shares of Class A common stock at a weighted average price of $4.78 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. Following the transaction, Reynoso directly holds 2,841,211 Clover Health shares, indicating the sale represents a very small portion of her total stake.
Clover Health CEO Jamie Reynoso sells $11,280 in class A stock By Investing.com
Clover Health CEO Jamie Reynoso sold 2,360 shares of Class A Common Stock for $11,280 on June 17, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred while Clover Health shares have surged 104% year-to-date and are near their 52-week high. The company recently reported mixed Q1 2026 earnings but received an upgraded Medicare star rating to 4.5 following a favorable court ruling.
Clover Health VP of finance Oldakowski sells $58,815 in stock
Joseph Frank Oldakowski, VP of Finance at Clover Health, sold 12,102 shares of Class A Common Stock for $58,815 on June 16, 2026. This transaction was a "sell to cover" to fulfill tax obligations for vesting restricted stock units (RSUs) and was not a discretionary trade. The sale occurred while Clover Health shares trade near their 52-week high, and the stock is considered overvalued by InvestingPro analysis despite a recent upgrade to a 4.5-star Medicare rating and mixed Q1 2026 earnings.
Clover Health VP of finance Oldakowski sells $58,815 in stock By Investing.com
Joseph Frank Oldakowski, VP of Finance at Clover Health, sold 12,102 shares worth $58,815 to cover tax obligations from vested restricted stock units. This "sell to cover" transaction was not discretionary and occurred as Clover Health's stock is up 110% year-to-date, trading near its 52-week high. The company recently reported mixed Q1 2026 earnings, but achieved a significant upgrade to a 4.5-Star Medicare rating following a favorable court ruling.
Clover Health VP of finance Oldakowski sells $58,815 in stock
Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health Investments Corp., sold 12,102 shares totaling $58,815 to cover tax withholding obligations for restricted stock units. This "sell to cover" transaction was not a discretionary trade, and Oldakowski still holds 299,067 shares. The sale comes as Clover Health's stock shows significant year-to-date returns and the company recently reported mixed Q1 2026 earnings but received a major upgrade in its Medicare star rating.
Clover Health (CLOV) finance VP sells 12,102 shares in tax-related RSU transaction
Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health, sold 12,102 shares of Class A Common Stock for $4.86 per share to cover tax withholding obligations related to the vesting of restricted stock units. This "sell to cover" transaction was mandatory and not a discretionary trade. Following the sale, Oldakowski directly holds 299,067 shares.
[144] CLOVER HEALTH INVESTMENTS, CORP. /DE SEC Filing
Clover Health Investments, Corp. filed a Form 144 on June 16, 2026, reporting the sale of 14,155 shares of Class A Common Stock. This transaction is related to the vesting of restricted stock units and is a routine resale notice under Rule 144. The filing indicates a neutral impact and sentiment, primarily outlining compliance elements for the sale of these compensation-related shares on Nasdaq.
Clover Health CEO Jamie Reynoso sells $29,273 in company stock By Investing.com
Clover Health CEO Jamie Reynoso sold 6,350 shares of the company's Class A Common Stock for $29,273 to cover tax withholding obligations related to restricted stock unit vesting. Following the sale, Reynoso directly owns 2,843,571 shares. Despite the stock trading near its 52-week high and delivering a 105% year-to-date return, InvestingPro analysis suggests it is overvalued, though the company recently reported strong Q1 2026 revenue and an upgraded Medicare star rating.
Clover Health CEO Jamie Reynoso sells $29,273 in company stock By Investing.com
Clover Health CEO Jamie Reynoso sold 6,350 shares of Class A Common Stock for $29,273, primarily to cover tax withholding obligations from vested restricted stock units. This "sell to cover" transaction was not discretionary. The sale comes as Clover Health's stock is performing well, with a 105% year-to-date return, and the company recently received a Medicare star rating upgrade to 4.5.
Clover Health chief legal officer Karen Soares sells $21,579 in stock
Clover Health's Chief Legal Officer, Karen Soares, sold 4,681 shares of the company's Class A Common Stock for a total of $21,579. These transactions were "sell to cover" to fulfill tax withholding obligations tied to restricted stock unit vesting, not discretionary trades. Following these sales, Ms. Soares still holds 1,567,741 shares of Clover Health.
Clover Health (CLOV) executive logs small tax-related sell-to-cover stock sale
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, sold 6,350 shares of Class A common stock on June 15, 2026, at a weighted average price of $4.61 per share. This sale was a non-discretionary "sell to cover" transaction to fulfill tax withholding obligations from vesting restricted stock units. After the sale, Reynoso directly holds 2,843,571 shares of Clover Health Class A common stock.
Clover Health (CLOV) legal chief sells 4,681 shares to cover taxes
Clover Health Investments' Chief Legal Officer, Karen Soares, sold 4,681 shares of Class A common stock at a weighted average price of approximately $4.61 per share. This was a mandated "sell to cover" transaction to fulfill tax obligations related to vesting restricted stock units (RSUs) and was not a discretionary trade. Following the sale, Soares directly holds 1,567,741 shares of Clover Health Class A common stock.
Clover Health CEO Jamie Reynoso sells $29,273 in company stock
Clover Health CEO Jamie Reynoso sold 6,350 shares of Class A Common Stock, totaling $29,273, to cover tax withholding obligations related to restricted stock units. This "sell to cover" transaction, occurring at a weighted average price of $4.61 per share, was not a discretionary trade. Following the sale, Mr. Reynoso directly owns 2,843,571 shares, and the company's stock is trading near its 52-week high, showing a 105% year-to-date return.
Clover Health (NASDAQ: CLOV) RSU vesting lists 5,342 Class A shares for sale
Clover Health Investments, Corp. (CLOV) has filed a Form 144 indicating a proposed sale of 5,342 Class A Common Stock shares. These shares are tied to the vesting of Restricted Stock Units (RSUs) on June 15, 2026, and will be traded on Nasdaq. The filing is neutral in sentiment and relates to employee compensation.
Clover Health (NASDAQ: CLOV) files Form 144 for 7,556 vested shares
Clover Health Investments, Corp. has filed a Form 144 notice for 7,556 vested Class A Common Stock shares with a proposed sale date of June 15, 2026. This routine filing is related to the vesting of restricted stock units. The document also indicates prior sales by Jamie Reynoso on March 18, 2026, and June 11, 2026, totaling 5,833 and 7,289 shares, respectively.
Clover Health (CLOV) stockholders approve directors, pay and 2026 auditor
Clover Health Investments, Corp. held its 2026 annual meeting on June 10, 2026, where stockholders elected three Class II directors: Demetrios L. Kouzoukas, Andrew Toy, and Thomas L. Tran. Shareholders also approved the 2025 compensation of named executive officers on a non-binding advisory basis and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company detailed voting results for each proposal, including specific vote counts for director elections, executive compensation approval, and auditor ratification.
Clover Health CEO Jamie Reynoso sells $35,788 of CLOV common stock
Clover Health Investments Corp. CEO Jamie L. Reynoso sold 7,289 shares of CLOV common stock for approximately $35,788 on June 11, 2026. This transaction occurred via a pre-arranged trading plan, with shares sold at prices between $4.79 and $5.15. The sale happened as the stock was near its 52-week high after a 108% year-to-date return, while InvestingPro analysis suggests the stock is currently overvalued.
Clover Health (NASDAQ: CLOV) exec sells 7,289 shares under 10b5-1 plan
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health (NASDAQ: CLOV), sold 7,289 shares of Class A Common Stock at a weighted average price of $4.91 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. Following the transaction, Reynoso directly retains 2,849,921 shares, indicating the sale represents a small portion of her overall holdings.
Breaking News: Rosen, Global Investor Counsel, Encourages Clover Health Investments, Corp. f/k/a Social Capital Hedosophia Holdings Corp. III Investors with Losses over $100K to Secure Counsel Before Important Deadline - CLOV, CLOVW, IPOC
Rosen Law Firm is encouraging investors of Clover Health Investments Corp. (CLOV, CLOVW, IPOC) who suffered losses exceeding $100,000 to seek legal counsel before the April 6, 2021 lead plaintiff deadline. The firm reminds purchasers of Clover securities during the Class Period (October 6, 2020, to February 4, 2021) that they may be entitled to compensation due to alleged false and misleading statements made by the company. The lawsuit claims that Clover failed to disclose a DOJ investigation into its platform, undisclosed related-party deals, and misleading marketing practices.
Clover Health Class Action Reminder
Faruqi & Faruqi, LLP is reminding investors of the April 6, 2021 deadline to seek the role of lead plaintiff in a federal securities class action against Clover Health Investments, Corp. The lawsuit alleges that Clover Health made false and misleading statements and failed to disclose critical information, including an active Department of Justice investigation and undisclosed related-party deals. Investors who suffered losses exceeding $50,000 between October 6, 2020, and February 4, 2021, are encouraged to contact the firm.
Clover Health CEO Conrad Wai sells $879k in company stock
Clover Health CEO Conrad Wai sold 220,426 shares of the company's Class A Common Stock for approximately $879,499 on May 28, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while CLOV stock was trading near its 52-week high, having surged 78% year-to-date. This event follows a mixed Q1 2026 earnings report where revenue exceeded expectations but EPS fell short.
Planned CLOV insider sale: officer trades 220K shares via family trust
Wai Conrad, an officer at Clover Health Investments, sold 220,426 shares of Class A Common Stock at an average price of $3.99 per share through a family trust. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025. Despite the sale, Conrad retains a significant stake in the company, holding over 2.5 million shares directly and indirectly.
Clover Health director Carladenise Edwards sells $229,687 in stock By Investing.com
Carladenise Edwards, a director at Clover Health Investments Corp. (NASDAQ:CLOV), sold 67,160 shares of Class A Common Stock for a total of $229,687 on May 18, 2026. The sale occurred while the stock was trading near $3.50, after a 46% gain over the previous six months. Despite the sale, InvestingPro analysis suggests Clover Health is undervalued, even as the company reported a mixed Q1 2026 with revenue exceeding expectations but EPS falling short.
Clover Health director Carladenise Edwards sells $229,687 in stock By Investing.com
Clover Health director Carladenise Edwards sold 67,160 shares of Class A Common Stock for a total of $229,687 on May 18, 2026. This transaction occurred as the stock trades near $3.50, having gained 46% over the past six months, and leaves Ms. Edwards with 285,432 shares directly owned. Despite the sale, InvestingPro analysis suggests Clover Health is currently undervalued, following a mixed Q1 2026 earnings report with revenue beating expectations but EPS falling short.
Clover Health director Carladenise Edwards sells $229,687 in stock
Carladenise Edwards, a director at Clover Health Investments Corp. (NASDAQ:CLOV), sold 67,160 shares of Class A Common Stock for $229,687 on May 18, 2026, with the stock trading near $3.50. This sale follows the company's recent Q1 2026 earnings report, which showed revenue exceeding analyst expectations but an earnings per share miss. Edwards now directly owns 285,432 shares of Clover Health Class A Common Stock.
Director at Clover Health (NASDAQ: CLOV) sells 67K shares at ~$3.42
A director at Clover Health (CLOV), Carladenise Armbrister Edwards, reported selling 67,160 Class A common shares at a weighted average price of approximately $3.42 per share. The individual orders ranged from $3.41 to $3.43. Following this transaction, Edwards directly holds 285,432 shares of Clover Health.
RSU vesting leads Clover Health (CLOV) interim CFO to tax share withholding
Clover Health's interim CFO, Joseph Clay, had 16,942 Class A shares automatically withheld at $3.47 per share on May 16, 2026, to cover tax obligations from RSU vesting. This tax withholding represents 6.25% of his original RSU grant from February 2024, with remaining RSUs vesting quarterly until February 2028, subject to continued service. Following this transaction, Clay directly holds 1,217,584 Class A shares.
[144] CLOVER HEALTH INVESTMENTS, CORP. /DE SEC Filing
This article details a Form 144 SEC filing by Clover Health Investments, Corp. (CLOV) concerning the proposed sale of 886,341 shares of Class A common stock by Fidelity Investments, acquired through a stock plan option on April 29, 2025. The filing indicates a neutral impact and sentiment, with an aggregate market value of over $3 million for the shares to be sold.
Clover Health CEO Brady Priest sells $345,097 in shares By Investing.com
Brady Patrick Priest, CEO of Clover Care Services, a subsidiary of Clover Health Investments Corp., sold 98,039 shares of Class A Common Stock for $345,097. Following this transaction, Mr. Priest still holds over 2 million shares. Despite analysts predicting profitability this year, InvestingPro analysis suggests CLOV is currently slightly overvalued.
Clover Health CEO Brady Priest sells $345,097 in shares By Investing.com
Brady Patrick Priest, CEO of Clover Care Services (a subsidiary of Clover Health Investments Corp.), sold 98,039 shares of Class A Common Stock for a total of $345,097 on May 13, 2026. This transaction leaves him with 2,040,222 shares. Despite the company appearing slightly overvalued, analysts are predicting profitability for the current year.
[Form 4] CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading Activity
Brady Patrick Priest, CEO of Clover Care Services, a subsidiary of Clover Health Investments, Corp. (CLOV), reported an open-market sale of 98,039 shares of Class A common stock at $3.52 per share on May 13, 2026. After this transaction, Priest directly holds 2,040,222 shares. This Form 4 filing indicates a moderate impact with a negative sentiment due to the insider selling shares.
Clover Health CEO Brady Priest sells $345,097 in shares
Clover Health CEO Brady Priest sold 98,039 shares of Class A Common Stock for $3.52 per share, totaling $345,097. Following this transaction, Priest directly holds over 2 million shares. Despite the sale, analysts predict Clover Health will be profitable this year, and Q1 2026 revenue exceeded expectations although EPS fell short.
[Form 4] CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading Activity
Clover Health Investments CEO Andrew Toy reported a tax-related share withholding on May 8, 2026, where 85,704 shares of Class A common stock were withheld to cover tax obligations on vesting restricted stock units (RSUs). This was a routine, non-open market transaction, common for equity compensation plans. Following this, Toy directly holds 9,923,301 shares, and the remaining RSUs will continue to vest quarterly until August 8, 2026.
Clover Health (NASDAQ: CLOV) turns Q1 2026 profit as Medicare Advantage revenue surges
Clover Health (NASDAQ: CLOV) reported a significant financial turnaround in Q1 2026, achieving a net income of $27.3 million compared to a loss in the prior year. This profitability was primarily fueled by a 62% surge in total revenues to $749.2 million, driven by substantial growth in Medicare Advantage membership and improved star ratings for its PPO plans. The company also demonstrated strengthened liquidity with operating cash flow of $107.9 million, indicating a positive outlook for funding growth initiatives.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Clover Health Investments, Corp. f/k/a Social Capital Hedosophia Holdings Corp. III Investors to Secure Counsel Before Important Deadline - CLOV, CLOVW, IPOC
The Rosen Law Firm is reminding investors of Clover Health Investments, Corp. (CLOV, CLOVW, IPOC) that the lead plaintiff deadline in a securities class action lawsuit is April 6, 2021. The lawsuit alleges that Clover Health made false and misleading statements regarding its business, operations, and prospects, specifically concerning a Department of Justice investigation, undisclosed related-party deals, and misleading marketing practices. Investors who purchased Clover securities during the Class Period (October 6, 2020, and February 4, 2021) or pursuant to the December 2020 merger are encouraged to contact the firm for compensation information.
Clover Health (CLOV) sets 2026 virtual meeting, director elections and Say-on-Pay vote
Clover Health Investments, Corp. (CLOV) announced its 2026 annual stockholder meeting will be held virtually on June 10, 2026. Stockholders will vote on the election of three Class II directors, a non-binding "Say-on-Pay" proposal for 2025 executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for 2026. The Board recommends voting "FOR" all proposals and has outlined its compensation philosophy focusing on pay-for-performance and aligning executive interests with stockholders.
Clover Health (CLOV) CEO RSU vesting triggers share tax withholding
Brady Patrick Priest, CEO of Clover Care Services, underwent a routine tax-withholding transaction where 36,113 Clover Health Investments Class A Common Stock shares were withheld at $2.19 each. This was to cover tax obligations from vested restricted stock units (RSUs). This transaction is a compensation-related tax settlement and not an open-market sale, leaving Priest with 2,138,261 shares.
Clover Health (CLOV) executive stock withheld to cover RSU tax bill
Clover Health Investments executive Brady Patrick Priest had 15,471 shares of Class A Common Stock withheld at $2.04 per share to cover tax obligations related to the vesting of restricted stock units (RSUs). This was an automatic tax-withholding event, not an open-market sale, and relates to 6.25% of an RSU grant from October 2024. Following the transaction, Priest directly holds 2,174,374 Class A shares, with remaining RSUs vesting quarterly until October 2028.
